Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/clinical-implications-of-mutations-in-the-pi3k-pathway-in-her2-breast-RN9sXnWueH
References (42)
-
Yujun Hao, Chao Wang, Bo Cao, Brett Hirsch, Jing Song, S. Markowitz, R. Ewing, D. Sedwick, Lili Liu, Weiping Zheng, Zhenghe Wang (2013)
Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.Cancer cell, 23 5
-
P. Eichhorn, M. Gili, M. Scaltriti, V. Serra, M. Guzman, Wouter Nijkamp, R. Beijersbergen, Vanesa Valero, J. Seoane, R. Bernards, J. Baselga (2008)
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.Cancer research, 68 22
-
A. Hanker, A. Pfefferle, J. Balko, M. Kuba, C. Young, V. Sanchez, Cammie Sutton, Hailing Cheng, C. Perou, Jean Zhao, R. Cook, C. Arteaga (2013)
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesProceedings of the National Academy of Sciences, 110
-
S. Loi, S. Michiels, D. Lambrechts, D. Fumagalli, B. Claes, P. Kellokumpu-Lehtinen, P. Bono, V. Kataja, M. Piccart, H. Joensuu, C. Sotiriou (2013)
Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast CancerJNCI Journal of the National Cancer Institute, 105
-
Chuangfang Huang, D. Mandelker, O. Schmidt-Kittler, Yardena Samuels, Yardena Samuels, V. Velculescu, K. Kinzler, B. Vogelstein, S. Gabelli, L. Amzel (2007)
The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα MutationsScience, 318
-
P Liu, H Cheng, S Santiago, M Raeder, F Zhang (2011)
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanismsNat Med, 17
-
V. Guarneri, M. Dieci, L. Carbognin, A. Maiorana, S. Bettelli, G. Tortora, P. Conte, E. Bria (2014)
254OACTIVITY OF NEOADJUVANT LAPATINIB (L) PLUS TRASTUZUMAB (T) FOR EARLY BREAST CANCER (EBC) ACCORDING TO PIK3CA MUTATIONS: PATHOLOGICAL COMPLETE RESPONSE (PCR) RATE IN THE CHERLOB STUDY AND POOLED ANALYSIS OF RANDOMIZED TRIALS.Annals of oncology : official journal of the European Society for Medical Oncology, 25 suppl_4
-
M. Pegram (2008)
Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?Clinical breast cancer, 8 Suppl 3
-
L. Gianni, G. Bianchini, A. Kiermaier, G. Bianchi, Y. Im, T. Pieńkowski, L. Roman, M. Liu, L. Tseng, J. Ratnayake, T. Szado, G. Ross, P. Valagussa (2011)
S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC).Cancer Research, 71
-
B. Rexer, C. Arteaga (2013)
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.Cancer research, 73 13
-
I. Krop, C. Saura, J. Ahnert, C. Becerra, C. Britten, S. Isakoff, D. Demanse, W. Hackl, C. Quadt, Antonio Silva, H. Burris, M. Abu-Khalaf, J. Baselga (2012)
A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.Journal of Clinical Oncology, 30
-
F. Esteva, Hua Guo, Siyuan Zhang, C. Santa-Maria, S. Stone, J. Lanchbury, A. Sahin, G. Hortobagyi, Dihua Yu (2010)
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.The American journal of pathology, 177 4
-
A. Chakrabarty, B. Rexer, S. Wang, R. Cook, J. Engelman, C. Arteaga (2010)
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3Oncogene, 29
-
J. Jensen, J. Jensen, Ann Knoop, A. Knoop, A. Laenkholm, M. Grauslund, M. Jensen, E. Santoni-Rugiu, M. Andersson, M. Ewertz, M. Ewertz (2012)
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.Annals of oncology : official journal of the European Society for Medical Oncology, 23 8
-
Yoichi Nagata, K. Lan, Xiaoyan Zhou, M. Tan, F. Esteva, A. Sahin, K. Klos, Ping Li, B. Monia, Nina Nguyen, G. Hortobagyi, M. Hung, Dihua Yu (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.Cancer cell, 6 2
-
K. Pogue-Geile, N. Song, Jong-Hyeon Jeong, P. Gavin, Seong-Rim Kim, Nicole Blackmon, Melanie Finnigan, P. Rastogi, L. Fehrenbacher, E. Mamounas, S. Swain, D. Wickerham, C. Geyer, J. Costantino, N. Wolmark, S. Paik (2015)
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 12
-
Pixu Liu, Hailing Cheng, Stephanie Santiago, M. Raeder, Fan Zhang, Adam Isabella, Janet Yang, D. Semaan, Changzhong Chen, E. Fox, N. Gray, J. Monahan, R. Schlegel, R. Beroukhim, G. Mills, Jean Zhao (2011)
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and -independent mechanismsNature medicine, 17
-
K. Berns, H. Horlings, B. Hennessy, M. Madiredjo, E. Hijmans, K. Beelen, S. Linn, A. González-Angulo, K. Stemke‐Hale, M. Hauptmann, R. Beijersbergen, G. Mills, M. Vijver, R. Bernards (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.Cancer cell, 12 4
-
S. Hurvitz, R. Pietras (2008)
Rational management of endocrine resistance in breast cancerCancer, 113
-
A. Contreras, S. Herrera, Tao Wang, I. Mayer, A. Forero, R. Nanda, M. Goetz, J. Chang, A. Pavlick, S. Fuqua, C. Gutierrez, S. Hilsenbeck, Marilyn Li, C. Osborne, R. Schiff, M. Rimawi (2013)
Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patientsCancer Research, 73
-
CH Huang, D Mandelker, O Schmidt-Kittler, Y Samuels, VE Velculescu (2007)
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutationsScience, 318
-
Lauren Thorpe, Haluk Yuzugullu, Jean Zhao (2014)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targetingNature Reviews Cancer, 15
-
SA Hurvitz, RJ Pietras (2008)
Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directionsCancer, 113
-
S. Hurvitz, F. André, Zefei Jiang, Z. Shao, M. Mano, S. Neciosup, L. Tseng, Qingyuan Zhang, K. Shen, Donggeng Liu, L. Dreosti, H. Burris, M. Toi, M. Buyse, David Cabaribere, M. Lindsay, S. Rao, L. Pacaud, T. Taran, D. Slamon (2015)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.The Lancet. Oncology, 16 7
-
J. Baselga, J. Cortés, S. Im, E. Clark, G. Ross, A. Kiermaier, S. Swain (2014)
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 33
-
S Loi, S Michiels, D Lambrechts, D Fumagalli, B Claes (2013)
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancerJ Natl Cancer Inst, 105
-
K. Kinross, K. Montgomery, Margarete Kleinschmidt, P. Waring, Ivan. Ivetac, A. Tikoo, Mirette Saad, Lauren Hare, V. Roh, T. Mantamadiotis, K. Sheppard, G. Ryland, I. Campbell, Kylie Gorringe, J. Christensen, C. Cullinane, R. Hicks, R. Pearson, R. Johnstone, G. McArthur, W. Phillips (2012)
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.The Journal of clinical investigation, 122 2
-
JT Garrett, CL Arteaga (2011)
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implicationsCancer Biol Ther, 11
-
Magdalena Čížková, Magdalena Čížková, M-E Dujaric, J. Lehmann-Che, V. Scott, O. Tembo, B. Asselain, J. Pierga, M. Marty, P. Crémoux, F. Spyratos, I. Bièche (2013)
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumabBritish Journal of Cancer, 108
-
J. Baselga, J. Cortes, S. Im, E. Clark, A. Kiermaier, G. Ross, S. Swain (2012)
Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)Cancer Research, 72
-
J. Baselga, J. Cortés, Sung-Bae Kim, S. Im, R. Hegg, Y. Im, L. Roman, J. Pedrini, T. Pieńkowski, A. Knott, E. Clark, M. Benyunes, G. Ross, S. Swain (2012)
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.The New England journal of medicine, 366 2
-
L. Bender, R. Nahta (2008)
Her2 cross talk and therapeutic resistance in breast cancer.Frontiers in bioscience : a journal and virtual library, 13
-
S. Loibl, I. Majewski, V. Guarneri, V. Nekljudova, E. Holmes, E. Bria, C. Denkert, H. Eidtmann, C. Sotiriou, S. Loi, F. André, M. Untch, P. Conte, M. Piccart-Gebhart, G. Minckwitz, J. Baselga (2015)
Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.Journal of Clinical Oncology, 33
-
F. André, R. O'Regan, M. Ozguroglu, M. Toi, Bing-he Xu, G. Jerusalem, N. Masuda, S. Wilks, F. Arena, C. Isaacs, Y. Yap, Z. Pápai, I. Láng, A. Armstrong, G. Lerzo, M. White, K. Shen, J. Litton, David Chen, Yufen Zhang, S. Ali, T. Taran, L. Gianni (2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.The Lancet. Oncology, 15 6
-
R. Nahta, Dihua Yu, M. Hung, G. Hortobagyi, F. Esteva (2006)
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancerNature Clinical Practice Oncology, 3
-
J. Engelman, Liang Chen, X. Tan, K. Crosby, A. Guimaraes, Rabi Upadhyay, Michel Maira, K. McNamara, Samanthi Perera, Youngchul Song, L. Chirieac, R. Kaur, Angela Lightbown, Jessica Simendinger, Timothy Li, R. Padera, C. García-echeverría, R. Weissleder, U. Mahmood, L. Cantley, Kwok-kin Wong (2008)
Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung CancersNature medicine, 14
-
S. Loibl, G. Minckwitz, A. Schneeweiss, S. Paepke, A. Lehmann, M. Rezai, D. Zahm, P. Sinn, F. Khandan, H. Eidtmann, Karel Dohnal, C. Heinrichs, J. Huober, B. Pfitzner, P. Fasching, F. André, J. Lindner, C. Sotiriou, August Dykgers, Sanxing Guo, S. Gade, V. Nekljudova, S. Loi, M. Untch, C. Denkert (2014)
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 29
-
Magdalena Čížková, Aurélie Susini, S. Vacher, G. Cizeron‐Clairac, C. Andrieu, K. Driouch, E. Fourme, R. Lidereau, I. Bièche (2012)
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroupsBreast Cancer Research : BCR, 14
-
J. Garrett, C. Arteaga (2011)
Resistance to HER2-directed antibodies and tyrosine kinase inhibitorsCancer Biology & Therapy, 11
-
I. Majewski, P. Nuciforo, L. Mittempergher, A. Bosma, H. Eidtmann, E. Holmes, C. Sotiriou, D. Fumagalli, J. Jiménez, C. Aura, L. Prudkin, Maria Díaz-Delgado, L. Peña, S. Loi, C. Ellis, N. Schultz, E. Azambuja, N. Harbeck, M. Piccart-Gebhart, R. Bernards, J. Baselga (2015)
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 12
-
J. Burke, O. Perisic, G. Masson, O. Vadas, Roger Williams (2012)
Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA)Proceedings of the National Academy of Sciences, 109
-
V. Serra, B. Markman, M. Scaltriti, P. Eichhorn, Vanesa Valero, M. Guzman, M. Botero, E. Llonch, F. Atzori, S. Cosimo, Michel Maira, C. García-echeverría, J. Parra, J. Arribas, J. Baselga (2008)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.Cancer research, 68 19
- Publisher
- Springer Journals
- Copyright
- Copyright © 2015 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-015-0197-9
- Publisher site
- See Article on Publisher Site
Abstract
Recent advances in tumor genetics and drug development have led to the generation of a wealth of anti-cancer-targeted therapies. These drugs aim at targeting a particular vulnerability in the tumor generated in most cases as a result of dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of the PI3K/AKT pathway has been shown to confer resistance to HER2-targeted therapies. Several drugs targeting PI3K/ATK have been developed and are currently in clinical trials in different phases of clinical development, alone or in combination. The impact of mutations in the phosphoinositide 3-kinase (PI3K)/AKT pathway in HER2-amplified breast cancers will be the focus of this review.
Journal
Current Breast Cancer Reports – Springer Journals
Published: Oct 10, 2015